Study for AZD4360 in Participants With Advanced Solid Tumours
← catalyst calendarNCT06921928 · readout in 224 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
31actual
Sites
14
Countries
China, Germany, Japan +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-29 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma
Intervention
- Drug: AZD4360
Primary outcome
what the primary-completion date above is the date OFIncidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360
measured Through study completion, up to approximately 2 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed